Plus Therapeutics Inc (NASDAQ:PSTV) shares traded 9.03% higher at $1.57 on Wall Street last session.
PSTV stock price is now 38.76% away from the 50-day moving average and 8.15% away from the 200-day moving average. The market capitalization of the company currently stands at $9.26M.
With the price target of $8, Ladenburg Thalmann recently initiated with Buy rating for Plus Therapeutics Inc (NASDAQ: PSTV). On October 16, 2020, Maxim Group recently initiated its ‘Buy’ rating on the stock quoting a target price of $6
In other news, Hawkins Richard J, Director bought 4,000 shares of the company’s stock on Sep 13 ’24. The stock was bought for $5,996 at an average price of $1.50. Upon completion of the transaction, the Director now directly owns 15,188 shares in the company, valued at $23845.16. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12 ’24, Director Hawkins Richard J bought 6,285 shares of the business’s stock. A total of $8,512 was incurred on buying the stock at an average price of $1.35. This leaves the insider owning 11,188 shares of the company worth $17565.16. A total of 2.55% of the company’s stock is owned by insiders.
During the past 12 months, Plus Therapeutics Inc has had a low of $0.24 and a high of $2.67.
The net profit margin was -225.07% and return on equity was -522.50% for PSTV. The company reported revenue of $1.46 million for the quarter, compared to $1.24 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17.42 percent. For the current quarter, analysts expect PSTV to generate $1.19M in revenue.
